

Shijiazhuang Pharmaceutical



石家庄制药集团有限公司
SHIJIAZHUANG PHARMACEUTICAL GROUP CO.,LTD.

中国·石家庄


董 事 长 致 辞

石家庄制药集团经过近几年的努力，迅速成长为中国医药行业举足轻重的大型制药企业。今天，正迈着坚实的步伐，踏上世界经济舞台。

面对新世纪的挑战，石药人已经有了更新的目标，“做好药，为中国”是我们对世人的庄严承诺，建立“享誉世界，百年不倒”的企业品牌，是我们的奋斗目标，“致力于全人类的健康和文明”是我们永恒的追求。

社会在发展，人类在进步，健康和长寿是人们的共同期望，我们将不负众望担当历史责任，以高科技、人格化的产品，热情周到的服务，在更为广泛的领域，以真诚的投入和无私的奉献精神，与各界同仁和朋友们一道，同心同德，开拓进取，为医药事业的明天和全人类的健康兢兢业业、严谨求索、不懈努力。

董事长



1

Address of the Directing Manager

After several years of efforts, SPG rapidly grew into a large pharmaceutical enterprise playing a decisive role in the medical industry of China . Today, it is developing steadily and integrates into the world economy.

Facing the challenge of the new century, the SPG people have set up new goals. "Making good medicines for China " is our solemn commitment to the world; setting up an enterprise brand that is "world famous and everstanding " is our aim struggling for; "contributing to the health and civilization of all the people " is our pursuit forever. To realize all the goals depends on the down-to-earth and hardworking SPG people.

With the developing of the society and progressing of human civilization, people pay more and more attention to health and long life. We will take it as our responsibility to make unremitting effort for the bright future of medical industry and the health of all the people. With our personified products, sincere and circumspect service, healthy and distingue philosophy, and together with friends from all circles, be of one heart and one mind and enterprising.

Directing Manager



亲切的关怀

Kind Attention

往日的辉煌

是留在历史上一抹印痕

存在的意义

不止于此

石药的追求

从背起责任的那一刻开始



1999年9月12日在邯钢座谈会上朱镕基总理亲切接见蔡东晨董事长
On Sep.12th,1999 Premier Zhu Rongji, on his inspection tour in Handan City,
kindly meet Mr.Cai Dongchen (Directing Manager)



1999年4月15日政协主席李瑞环来石药视察，
与蔡东晨董事长亲切交谈
Li Ruihuan, the standing member of Political Bureau of
Chinese Communist Party Central Committee & Chairman of
National Political Consultative Conference, comes to inspect the plant in person.

做

好

殷切的希望

Ardent Expectations



1999年8月12日江泽民总书记在八省区国企改革与发展座谈会上亲切接见蔡东晨董事长

On Aug. 12th, 1999 President Jiang Zemin cordially views with Mr. Cai Dongchen (Directing manager)
on the discussion conference for state-owned enterprises reforms in Dalian City.

2AL17/02

药

为

中

国

Group Brief




1998 石药集团部分指标全国排名 A Part of SPG. Production Target Rank In China

项目 Item	全国同行业排名 National Same Profession Rank
工业总产值 Industrial total output value	3
销售收入 / 利润 Sales income, profit	4
青霉素 / VC 产量 Penicillin, VC output	2
粉针分装能力 Dividing powder injection into package capacity	2
7-ACA 产量 7-ACA output	1
头孢产品产量 Cefal output	2
柯柯豆碱产量 Thebromine output	1
阿莫西林产量 Amoxicillin output	1
咖啡因产量 Caffeine output	1
氨苄西林钠产量 Ampicillin output	2
大输液产量 Large infusion output	1

石家庄制药集团有限公司组织结构图

Structure of SHIJIAZHUANG PHARMACEUTICAL GROUP CO.;LTD.Organization



公司简介

Group Brief

石家庄制药集团有限公司是中国医药行业首家通过强强联合组建的大型制药企业,从事医药产品的开发、生产和销售,制药技术和产品已拓展到临床用药的多个领域。

公司拥有 30 余家全资和控股公司,其中设在香港的控股子公司“中国制药企业投资有限公司”1994年6月在香港联交所挂牌上市,是中国医药行业第一家境外上市公司,目前已成为香港红筹股,表现优秀。公司总部设在河北省省会石家庄市,现有员工12000人,1998年资产总额达35亿元,年销售额为30亿元,是中国医药工业的骨干企业。

公司拥有多样化的医药产品,从西药到传统中药、从医药保健品到动物药品、从精细化工到卫生材料等,产品领域不断延伸,特别是在抗生素、化学合成药以及生物药品方面具备了丰富的生产经验。抗生素类、维生素类产品的各项技术及经济指标稳居国内同行业前列,部分产品技术指标已达到国际领先水平。产品畅销国内三十多个省市,并通过设在世界各地的销售网络,销往五大洲的五十多个国家和地区。

SHIJIAZHANG Pharmaceutical Group Co.Ltd.(hereinafter shortened as SPG) is the first extra large pharmaceutical enterprise in medical industry of China established through cooperation of several influential companies. It specially engaged in the development, production and marketing of medical products, and its pharmaceutical technologies and products have expanded to many fields of clinical medical treatment.

In total, the Company has more than 30 subsidiaries, among which China Pharmaceutical Enterprise Investment Co.,Ltd. a holding subsidiary company registered by the Company in Hong Kong, is the first company listed and marketed at foreign stock market of the medical industry of China. At present, it behaves well in Red Chip of the Hong Kong stock market.

The Company arranged its head office at Shijiazhuang City that is the capital of Hebei province and has a staff of 12000. By the end of 1998, the Company has a total asset of RMB 3.5 billion and annual turnover of RMB 3 billion, and it is a key enterprise of the medical industry of China.

The company has diversified medical products, such as products from Western medicine synthetic to traditional Chinese medicine, from health care products to animal medicines, from fine chemical to hygienic material. Its development scope is expanding continuously and rich experiences are collected, especially, in such fields as antibiotic, chem-synthetic medicine and biologic medicine. The technical indices of its products of synthetic penicillin category, semisynthetic antibiotic category and vitamin category constantly remain the best in the same trade, and the technical indices of part of the products have reached the international leading levels. Through its marketing network all over the world, the products are exported to more than 50 countries and areas.

Shijiazhuang Pharmaceutical

科技进步是石药人永恒的追求

不断迎接新的挑战

在挑战中完善自我

以坚实的规模和实力为人类奉献品质优良的产品



What Shiyao staff unremittingly strive for is scientific progress


Make self-improvement continuously by


facing and fighting all challenges

Contributing human beings high quality products

based on its scale and strength







Shijiazhuang Pharmaceutical

中国最重要的西药原料药专业生产基地

中国最大的头孢类抗生素生产基地

中国最主要的综合制剂生产基地




11

The most major production base for pharmaceutical raw materials of western drugs in China.

The largest production base for cephalosporin sector in China.

The most comprehensive production base for various prepared drugs in China.



China Pharmaceutical

China Pharmaceutical Enterprise Investment Co., Ltd., Hong Kong (hereinafter shortened as "China Pharmaceutical") is a holding subsidiary company registered by SPG in Hong Kong in 1992. approved by the Ministry of Foreign Economic Relations and Trade. It mainly engaged in investment on pharmaceutical industry and international trade of reative produdts of SPG .In 1994, approved by China Stock Supervsion Council and Hong Kong United Stock Exchange, "China Pharmaceutical" issued in Hong Kong and they came into the market successfully. It is the first pharmaceutical company that is controlled by Chinese party investment came into foriegn stock market. At present, it is one of the 32 constituent stocks for index of Hengsheng Red Chip, Hong Kong . "China Pharmaceurical put benefit of shareholders at the first place, and the share price and market value of the listed company increased rapidly because of supports and cares of stockjobbers. For 5 years of unremitting efforts, now it has 9 solely owned or holding subsidiaries inside china. The invested products involved 7 categories and near 20 main products, including vitamin C and its derived product series; further processed product series for Penicillin. Ampicillin, Amoxil etc; vitamin B12. theobromine, Indomethacin, 7-ACA, cephalosporin series and so on, about twenties products.

In 1998, "China Pharmaceutical" has won the second prize in the best Hong Kong United Stock Exchange. Selection Which hold by <Hong Kong Economic Journal> for its magnificent achievement in the market.



"China Pharmaceutical" will offer international pharmaceutical information, experiences and financial resources for the development of China's pharmaceutical industry in the way of various financial operation.


中国制药

香港中国制药企业投资有限公司（下称“中国制药”）是经国家外经贸部批准，由石药集团于1992年在香港注册设立的一家控股子公司，主要从事对制药行业的投资与集团相关产品的国际贸易。1994年，经中国证监会、香港联交所批准，“中国制药”在香港成功发行股票并上市，成为中国医药行业第一家境外上市公司，目前是香港恒生红筹股指数32家成份股之一。“中国制药”把股东利益放在首位，股东的支持和关爱使公司股份和市值迅速增加。经过五年不懈努力，已在国内拥有九家全资或控股子公司，所投资的产品包括维生素C及其系列衍生产品、青霉素及氨苄西林、阿莫西林等系列深加工产品、维生素B12、柯柯豆碱、己酮可可豆碱、7-ACA、头孢菌素等二十多种主要产品。

1998年，“中国制药”以其良好的业绩和市场表现，在香港《信报》评选的最佳红筹股中列第二位。

“中国制药”作为石药集团设在香港控股的上市公司，并作为国际资产市场的“融资窗口”，今后将通过灵活多样的资本运营活动，为中国制药的发展提供国际制药信息和经验以及资本来源。







集团总部外景
A View of SPG Headquarters



氨苄青霉素钠原料生产区
Ampicillin Production Area



维生素C原料生产区
Ascorbic Acid Production Area